Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Risk of Chronic Obstructive Pulmonary Disease Exacerbation in Patients Who Use Methotrexate-A Nationwide Study of 58,580 Outpatients

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. The Importance of Lipoprotein Lipase Regulation in Atherosclerosis

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. The Phenotypic Spectrum of PRRT2-Associated Paroxysmal Neurologic Disorders in Childhood

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Identification of Novel Native Autoantigens in Rheumatoid Arthritis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Heart failure associated with imported malaria: a nationwide Danish cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Alfa-1 Antitrypsinmangel

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Hydroxychloroquine as a primary prophylactic agent against sars-cov-2 infection: a cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Cardiac arrhythmias in patients hospitalized with COVID-19: The ACOVID study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Christina Marisa Bergsøe
  • Pradeesh Sivapalan
  • Mohamad Isam Saeed
  • Josefin Eklöf
  • Zaigham Saghir
  • Rikke Sørensen
  • Tor Biering-Sørensen
  • Jens-Ulrik Stæhr Jensen
Vis graf over relationer

Patients with severe chronic obstructive pulmonary disease (COPD) experience frequent acute exacerbations and require repeated courses of corticosteroid therapy, which may lead to adverse effects. Methotrexate (MTX) has anti-inflammatory properties. The objective of this study was to describe the risk of COPD exacerbation in patients exposed to MTX. In this nationwide cohort study of 58,580 COPD outpatients, we compared the risk of hospitalization-requiring COPD exacerbation or death within 180 days in MTX vs. non-MTX users in a propensity-score matched study population as well as an unmatched cohort, in which we adjusted for confounders. The use of MTX was associated with a reduction in risk of COPD exacerbation in the propensity-score matched population at 180 days follow-up (HR 0.66, CI 0.66-0.66, p < 0.001). Similar results were shown in our sensitivity analyses at 180-day follow-up on unmatched population and 365-day follow-up on matched and unmatched population (HR 0.76 CI 0.59-0.99, HR 0.81 CI 0.81-0.82 and HR 0.92 CI 0.76-1.11, respectively). MTX was associated with a lower risk of COPD exacerbation within the first six months after study entry. The finding seems biologically plausible and could potentially be a part of the management of COPD patients with many exacerbations.

OriginalsprogEngelsk
Artikelnummer604
TidsskriftBiomedicines
Vol/bind9
Udgave nummer6
ISSN2227-9059
DOI
StatusUdgivet - jun. 2021

ID: 66309620